Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021239880 - NUCLEIC ACID BASED COMBINATION VACCINES

Publication Number WO/2021/239880
Publication Date 02.12.2021
International Application No. PCT/EP2021/064216
International Filing Date 27.05.2021
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 2039/55555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
A61K 2039/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
70Multivalent vaccine
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61P 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
Applicants
  • CUREVAC AG [DE]/[DE]
Inventors
  • OOSTVOGELS, Cornelia
  • PETSCH, Benjamin
  • RAUCH, Susanne
  • SCHWENDT, Kim Ellen
Agents
  • GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH
  • VON STOSCH, Andreas
  • EICHELBAUM, Kornelia
  • LEHMBACHER, Michael
  • SCHARPING, Marion
Priority Data
PCT/EP2020/06509429.05.2020EP
PCT/EP2021/05245803.02.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NUCLEIC ACID BASED COMBINATION VACCINES
(FR) VACCINS COMBINÉS À BASE D'ACIDE NUCLÉIQUE
Abstract
(EN) The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.
(FR) La présente invention concerne, entre autres, des compositions pharmaceutiques comprenant au moins un acide nucléique codant pour au moins un peptide ou une protéine antigénique provenant d'un coronavirus, de préférence un coronavirus pandémique, et au moins un acide nucléique codant pour au moins un peptide ou une protéine antigénique provenant d'un autre virus, par exemple un virus de la grippe ou un virus VRS. Les compositions pharmaceutiques selon l'invention sont appropriées pour être utilisées dans le traitement ou la prophylaxie d'une infection par au moins un coronavirus et d'au moins une autre infection virale, et peuvent donc être comprises dans un vaccin combiné. Les séquences d'acides nucléiques des compositions pharmaceutiques et des vaccins combinés sont de préférence en association avec un support polymère, un peptide ou une protéine polycationique, ou une nanoparticule lipidique (LNP). L'invention concerne également des première et seconde utilisations médicales et d'autres utilisations médicales des compositions pharmaceutiques et des vaccins combinés, et des méthodes de traitement ou de prévention d'une infection à coronavirus et d'une autre infection virale.
Related patent documents
Latest bibliographic data on file with the International Bureau